Ibogaine Treatment in Mexico

Mexico is where most people who travel for ibogaine end up, and the reason is legal rather than medical. Understanding which kind of legal it is changes what you should ask when you get there.

The reason is an absence, not a permission

Ibogaine is not named among the psychotropic substances listed in Article 245 of Mexico’s General Health Law. Nothing in the drug law reaches it, so possessing and administering it is not a drug offence.

That is the whole of the legal position, and it is worth being precise about what it is not. No Mexican regulator has assessed ibogaine for safety or efficacy. No authority has approved its use in treatment. Nothing has been decided in its favour; it simply has not been decided about. The full picture, including what we were and were not able to verify against Mexican registries, is on ibogaine and Mexican law.

What that means when choosing

Because no standard is imposed from outside, the differences between providers are entirely internal to them, and two clinics in the same town can be running quite different levels of medical cover behind similar websites.

The questions that separate them are the ones about the heart, because that is what the published deaths run through. Ibogaine lengthens the QT interval, the lengthening produces no sensation, and deaths in the fatality series occurred as late as 76 hours after the dose. So the useful questions are whether a 12-lead ECG is taken and read before dosing, whether potassium and magnesium are corrected first, whether monitoring is continuous through the night, and whether there is a defibrillator in the room with someone trained to use it.

Ibogaine and the heart explains what each of those is for. How to judge a clinic carries the full question set, including the one worth asking first: what would make you refuse me.

Practical matters that are specific to travelling

Distance changes the shape of the risk in ways worth planning for.

You will be at the end of a journey, possibly dehydrated, on the day screening should happen. Electrolytes are exactly what long travel disturbs, and low potassium lengthens the QT interval further. Screening on arrival rather than before departure is common and worth questioning.

Bringing your medication list matters more than usual, because interactions with QT-prolonging drugs are the other documented amplifier, and a clinic cannot check what it is not told. Opioid substitution drugs, which prolong the QT interval themselves, are the recurring example.

Ask, before paying, what happens if someone needs a hospital: which one, how far, who accompanies, and who pays. It is a question with a specific answer at well-run places and a vague one elsewhere.

What the research record does and does not show

The most cited recent study of ibogaine, on veterans with traumatic brain injury, was conducted at a clinic in Mexico and reported no bradycardia, tachycardia, clinically meaningful QT prolongation or haemodynamic instability among 30 participants who received ibogaine with intravenous magnesium.

That result is often quoted as evidence that Mexican clinics are safe. It is not. It describes one protocol at one place with a screened, self-selected cohort of thirty male special-operations veterans, and its authors say plainly that it was not a randomised trial. It says nothing about the provider down the road.

What ibogaine treatment costs, and why quoted figures from Mexican providers are hard to compare, is on what ibogaine treatment costs.